Brief: Egetis Therapeutics Q1 Loss SEK 94.5 Mln
April 29 (Reuters) - Egetis Therapeutics AB (publ) EGTX.ST: EGETIS THERAPEUTICS Q1 REVENUE SEK 13.4 MILLION EGETIS THERAPEUTICS Q1 ADJUSTED EPS SEK -0.2 Q1 LOSS MSEK -94.5 (-62.9) Source text: ID:nMFN145NVv Further company coverage: EGTX.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Egetis Therapeutics AB (publ)
See all newsBrief: Egetis Announces Grant Of Patent For MCT8 Deficiency Composition In U.S.
Swedisg drugmaker Egetis's Q1 revenue rises 9% on Emcitate sales in Europe
Brief: Egetis Therapeutics Q1 Loss SEK 94.5 Mln
Brief: Egetis Plans Directed Share Issue Raising SEK 350 Million
Brief: Egetis Therapeutics Appoints Tiago Nunes As CMO Effective May 1